HomeESC 2016Highlights ESC 2016

Highlights ESC 2016

Andexanet Alfa: a Good Antidote against Anti Xa Agents

Andexanet alfa induces rapid reversion of Xa inhibitor effect in patients with active major bleeding, according to...

DES: Best Option in Saphenous Vein Grafts

These results confirm that, despite being used less and less worldwide, DES (drug eluting stents) are the...

OCT Improves Outcomes in Non ST Elevation ACS

This study presented at the ESC and simultaneously published in Circulation, is the first randomized controlled study...

Patients with Plaque Erosion: Management without Stenting

This small study presented at ESC and simultaneously published in the European Heart Journal evaluated patients undergoing acute coronary...

Six Month DAPT Enough for Nobori BES

Patients treated with A9 biolimus eluting stent with biodegradable polymer (Nobori, Terumo) can receive only six months...

Current Bare-Metal Stents: Similar to DES in the Very Long-Term

The largest randomized trial in history found no difference in the primary endpoint of death and nonfatal...

Primary PCI: Similar Results During Day and Night

Patients with ST-segment elevation myocardial infarction included in the CHAMPION PHOENIX trial admitted during nights, weekends, and...

Prasugrel vs. Ticagrelor in Primary Angioplasty

The choice of prasugrel or ticagrelor for patients with acute myocardial infarction undergoing primary angioplasty makes no...